C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cccc · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$7.00
Consensus
$7.00
+95.0% upside
Low
$7.00
Median: $7 · Last Close: $3.59
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.77 | ↑ 5.00% |
1-day model range: $3.72–$3.82. Peak: $3.82 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CCCC · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-01 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-02-27 | Barclays | Maintains | Overweight→Overweight |
| 2026-02-23 | Brookline Capital | Maintains | Buy→Buy |
| 2025-12-17 | Barclays | Maintains | Overweight→Overweight |
| 2025-09-23 | Wells Fargo | Maintains | Overweight→Overweight |
| 2025-09-23 | Barclays | Maintains | Overweight→Overweight |
| 2025-09-22 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2025-09-15 | Stephens & Co. | Upgrade ↑ | Equal Weight→Overweight |
| 2024-12-19 | Wells Fargo | Upgrade ↑ | Equal Weight→Overweight |
| 2024-08-06 | BMO Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on C4 Therapeutics, Inc. (CCCC) stock. Of the recent 45 rating actions, 5 were upgrades and 2 were downgrades. 14 analysts currently cover CCCC.
Analyst Recommendation Trends
CCCC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$23M
↑ 24.7% YoY
Revenue Next Year
$20M
↓ 11.8% YoY
EPS This Year
$-0.94
EPS Next Year
$-1.01
↑ 7.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CCCC EPS of $-0.94 for the current fiscal year, based on estimates from 4 analysts. The CCCC revenue forecast is $23M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CCCC stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CCCC price target is $7.00 (+95.0% upside), with an analyst consensus of Buy.
The CCCC short-term stock prediction for tomorrow is $3.77 (+5.00%). The CCCC stock price prediction for 2027 estimates an average of $2. The CCCC stock prediction for 2030 projects a range of $1–$1.
C4 Therapeutics, Inc. trades on NASDAQ under the ticker CCCC. The CCCC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
CCCC forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month CCCC price target is $7.00, with a high forecast of $7.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +95.0% potential upside from the current price of $3.59.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.